Aprogen, Inc
Financials
Valuation Metrics
Aprogen, Inc's Market Cap is ₩496B. At end of 2025 it was ₩173B. Ranked #1778 of 2,421 in KR market (top 73%), #692 of 781 on KOSPI (top 89%), #294 of 361 in Capital Goods (top 81%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 49.58B KRW | KR#1,778/2,421 Sec#294/361 |
| Revenue | 138.90B KRW | KR#1,233/2,421 Sec#205/361 |
| Net Income | -138.64B KRW | KR—/2,421 Sec—/361 |
| Total Assets | 674.45B KRW | KR#628/2,421 Sec#116/361 |
| Net Assets | 414.25B KRW | KR#584/2,421 Sec#105/361 |
| Employees | 296 | KR#801/2,421 Sec#142/361 |
| Value | ||
| P/B | 0.12x | KR#29/2,421 Sec#5/361 |
| P/S | 0.36x | KR#689/2,421 Sec#99/361 |
| FCF Yield | -79.28% | KR—/2,421 Sec—/361 |
| Profitability | ||
| ROE | -33.47% | KR#2,209/2,421 Sec#330/361 |
| ROA | -20.56% | KR#2,247/2,421 Sec#342/361 |
| Op. Margin | -66.42% | KR#2,266/2,421 Sec#339/361 |
| Revenue Growth | 9.08% | KR#952/2,421 Sec#147/361 |
| Financial Health | ||
| Debt Ratio | 62.81% | KR#1,130/2,421 Sec#135/361 |
| Total Debt | 179.80B KRW | KR#544/2,421 Sec#96/361 |
| FCF | -39.30B KRW | KR#2,034/2,421 Sec#299/361 |
| Cash | 37.89B KRW | KR#880/2,421 Sec#155/361 |
| Current Ratio | 0.83x | KR#1,910/2,421 Sec#306/361 |
| Dividend | ||
| Div. Yield | 0.00% | KR#1,394/2,421 Sec#227/361 |
| Performance | ||
| 1Y Return | 173.94% | KR#59/2,421 Sec#10/361 |
| 1M Return | -16.09% | KR#2,258/2,421 Sec#344/361 |
| From 52W High | -74.40% | KR#2,277/2,421 Sec#348/361 |
| 1Y MDD | -70.98% | KR#2,030/2,421 Sec#298/361 |
| Trading | ||
| Volume | 92,678 shares | KR#818/2,421 Sec#162/361 |
| Trading Value | 186.4M KRW | KR#1,306/2,421 Sec#241/361 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/361 |
| Per Share | ||
| EPS | -5,584 KRW | KR—/2,421 Sec—/361 |
| BPS | 16,686 KRW | KR#631/2,421 Sec#108/361 |
Company Info
Aprogen, established in 1971 and listed in 1995, completed a merger with a biopharmaceutical development company in 2022. Its subsidiary, Aprogen Biologics, formed a biopharmaceutical division in 2022, while N2TEC specializes in semiconductor component manufacturing and sales. Another subsidiary, APTEN, is engaged in geothermal heating/cooling, fuel cells, lithium, brain disease treatment, and virtual asset businesses. The company maintains a diversified business portfolio including hardfacing, steel, pharmaceuticals, insulation, bio, semiconductors, and renewable energy. Aprogen is headquartered in Seongnam-si, Gyeonggi-do.